|Bid||40.02 x 800|
|Ask||0.00 x 800|
|Day's Range||55.88 - 61.28|
|52 Week Range||45.11 - 63.38|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.75|
PLEASANTON, Calif., Nov. 07, 2019 -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the third quarter ended September 30, 2019. Recent Highlights.
PLEASANTON, Calif., Oct. 25, 2019 -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2019 after market close on Thursday,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...
PLEASANTON, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its Class A common stock, at a public offering price of $39.00 per share. All of the shares were offered by 10x Genomics. Registration statements relating to these securities have been filed with the Securities and Exchange Commission, and became effective on September 11, 2019.
PLEASANTON, Calif., Sept. 12, 2019 -- 10x Genomics, Inc. (“10x Genomics”) today announced the pricing of its initial public offering of its Class A common stock at a price of.
10x Genomics plans to sell up to 9 million shares of Class A common stock at a price between $31 and $35 per share, according to documents filed with the U.S. Securities and Exchange Commission. 10x Genomics also plans to grant the underwriters an option for a period of 30 days to purchase up to 1.35 million additional shares at the IPO price.